IPPK Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HeLa cells, designed to disrupt the IPPK (inositol pentakisphosphate 2-kinase) gene. This model provides a heterogeneous pool of knockout alleles, offering a robust loss-of-function system for investigating IPPK-dependent processes without the biases associated with clonal selection. The product is ideal for research into inositol phosphate metabolism, DNA repair mechanisms, and chromatin remodeling dynamics.
The parental HeLa cell line is an HPV18-positive cervical adenocarcinoma of epithelial origin, characterized by the expression of viral E6 and E7 oncoproteins that inactivate p53 and Rb tumor suppressors. This genetic background is extensively utilized in cancer research, offering reproducible growth kinetics and high transfection efficiency, which facilitates a wide range of downstream functional assays.
IPPK encodes the terminal kinase in the synthesis of inositol hexakisphosphate (InsP6), catalyzing the conversion of inositol 1,3,4,5,6-pentakisphosphate (InsP5) to InsP6. InsP6 serves as a multifunctional signaling molecule that directly binds and activates DNA repair kinases such as ATM and DNA-PKcs, thereby promoting DNA double-strand break repair. InsP6 also interacts with chromatin remodeling complexes, influencing genomic stability and transcriptional regulation. IPPK activity is stimulated by growth factor receptors and acts downstream of the PI3K pathway, integrating extracellular cues with inositol phosphate metabolism. IPPK further collaborates with other inositol phosphate kinases and components of the DNA repair apparatus, underscoring its pivotal role in maintaining cellular homeostasis.
In HeLa cells, disruption of IPPK is particularly pertinent due to the compromised p53 checkpoint, which heightens reliance on alternative DNA repair pathways. Reduced InsP6 production may impair DNA damage responses, sensitizing these cells to genotoxic agents and enabling exploration of synthetic lethal interactions. This model offers a valuable platform for studying how HPV oncoproteins intersect with host DNA repair and metabolic networks, providing insights into cervical cancer pathogenesis.
Research applications encompass quantifying InsP6 levels by mass spectrometry, monitoring DNA damage via ??-H2AX foci formation, assessing ATM and DNA-PKcs phosphorylation by western blotting, and evaluating cytotoxicity induced by DNA-damaging compounds. The cells are well-suited for drug target validation in oncology and metabolic disease contexts. For further information or technical support, please contact Ascent Research.
